Aadanaha CYP2C9 iyo VKORC1 Gene Polymorphism

Warfarin waa daawada xinjirowga lidka ku ah afka ee sida caadiga ah loo isticmaalo waxqabadka kiliinikada hadda, kaas oo inta badan loogu talagalay ka hortagga iyo daaweynta cudurrada thromboembolic.Si kastaba ha ahaatee, warfarin waxay leedahay daaqad daawaynta xaddidan oo aad ugu kala duwan jinsiyadaha iyo shakhsiyaadka kala duwan.Tirakoobyadu waxay muujiyeen in farqiga qiyaasta deggan ee shakhsiyaadka kala duwan ay ka badan karto 20 jeer.Dhiigbaxa falcelinta xun wuxuu ku dhacaa 15.2% bukaanada qaata warfarin sanad walba, kuwaas oo 3.5% ay yeeshaan dhiigbax dilaa ah.Daraasadaha farmashiyaha ayaa muujiyay in polymorphism-ka hidda-socodka ee bartilmaameedka enzyme VKORC1 iyo dheef-shiid kiimikaadka CYP2C9 ee warfarin ay tahay arrin muhiim ah oo saameynaysa farqiga u dhexeeya qiyaasta warfarin.Warfarin waa ka hortag gaar ah oo fiitamiin K epoxide reductase (VKORC1), oo sidaas awgeed waxay joojisaa isku-dhafka xinjirowga ee ku lug leh fitamiin K wuxuuna bixiyaa xinjirowga lidka ku ah.Tiro badan oo daraasado ah ayaa muujiyay in hidda-wadaha polymorphism-ka ee dhiirrigeliyaha VKORC1 ay tahay qodobka ugu muhiimsan ee saameeya jinsiyadda iyo kala duwanaanshaha shakhsi ahaaneed ee qiyaasta loo baahan yahay ee warfarin.Warfarin waxaa metabolized by CYP2C9, iyo mutants si aad u gaabis ah dheefshiidka warfarin.Shakhsiyaadka isticmaala warfarin waxay leeyihiin khatar sare (laba ilaa saddex jeer ka badan) dhiigbaxa marxaladda hore ee isticmaalka.